Table_4_PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China.doc
Our previous economic assessment found that nivolumab was not cost-effective for Chinese patients with advanced non-small cell lung cancer (NSCLC) and without EGFR mutations or ALK translocations, when compared with the standard second-line drug docetaxel. However, a greater survival benefit with nivolumab was observed for patients with 1% or greater tumor programmed death ligand 1 (PD-L1) expression. In view of this, we designed the present analysis to explore whether it is cost-effective to use the PD-L1 test to guide second-line nivolumab treatment in China.
Material and MethodsA Markov model was established to project the lifetime costs and quality-adjusted life-years (QALYs) of three second-line treatment strategies: nivolumab and docetaxel (strategies without a PD-L1 test) and PD-L1 test-based strategy. Deterministic and probabilistic sensitivity analyses were performed to examine the robustness of our results. Additional price reduction and willingness-to-pay (WTP) threshold scenario analyses were performed to explore the impact of economic and health policies with Chinese characteristics on our results.
ResultsThe PD-L1 test-based strategy costs approximately CNY 194,607 (USD 28,210) or more and yielded an additional 0.27 QALYs compared to the docetaxel strategy without a PD-L1 test, equating an incremental cost-effectiveness ratio (ICER) of CNY 731,089 (USD 105,978)/QALY. Deterministic sensitivity analyses showed that the price of nivolumab was the strongest source of variation in the ICERs. Probability sensitivity analysis showed that the probability for the PD-L1 test-based strategy being cost-effective increases with the increase of WTP thresholds.
ConclusionFrom the perspective of the Chinese healthcare system, using a PD-L1 test to guide second-line nivolumab treatment was not cost-effective. The National Healthcare Security Administration negotiation on the price reduction of nivolumab was found to be the most effective action to improve its cost-effectiveness in China.
History
References
- https://doi.org//10.3322/caac.21338
- https://doi.org//10.1056/NEJMra1703413
- https://doi.org//10.3322/caac.21551
- https://doi.org//10.1111/cas.14410
- https://doi.org//10.1200/JCO.19.00934
- https://doi.org//10.1016/j.jtho.2019.01.006
- https://doi.org//10.1038/nature14011
- https://doi.org//10.1158/1078-0432.CCR-13-3271
- https://doi.org//10.6004/jnccn.2019.0059
- https://doi.org//10.1007/s40261-019-00869-3
- https://doi.org//10.1007/s41669-020-00245-4
- https://doi.org//10.1080/13696998.2021.1917139
- https://doi.org//10.1016/j.lungcan.2020.11.013
- https://doi.org//10.1186/1471-2288-11-139
- https://doi.org//10.1371/journal.pone.0048323
- https://doi.org//10.1186/1471-2407-14-984
- https://doi.org//10.1371/journal.pone.0032530
- https://doi.org//10.1371/journal.pone.0151846
- https://doi.org//10.2217/cer-2017-0069
- https://doi.org//10.1111/ajco.12477
- https://doi.org//10.1371/journal.pone.0205827
- https://doi.org//10.1371/journal.pone.0088881
- https://doi.org//10.1001/jamaoncol.2018.7086
- https://doi.org//10.3779/j.issn.1009-3419.2020.02.01
- https://doi.org//10.1016/j.jtho.2016.05.032